Programmed cell death: a promising management for Alzheimer’s disease

Mar 29, 2026Apoptosis : an international journal on programmed cell death

Programmed cell death as a potential treatment for Alzheimer's disease

AI simplified

Longevity & Aging on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

Alzheimer's disease (AD) has a rising mortality rate, highlighting a significant health challenge among older adults.

(PCD) is a genetically regulated process essential for cellular health and organismal development.
Research indicates various forms of PCD, including and ferroptosis, may be linked to the onset and progression of AD.
Recent advances suggest PCD could aid in identifying biomarkers for AD and inspire new therapeutic approaches.
Challenges exist in utilizing PCD for AD management, but there are emerging opportunities for preventive strategies.

AI simplified

Epidemiological investigations have indicated that Alzheimer's disease (AD) has emerged as a predominant health challenge among older adults, with its mortality rate rising sharply each year. Nevertheless, measures capable of delaying or halting its clinical progression have remained largely unattained until recent years. (PCD), defined as a genetically regulated and orderly mode of cellular demise, is pervasive throughout organismal development and essential for maintaining life homeostasis. As research on PCD in AD has expanded, accumulating evidence has shown that , ferroptosis, cuproptosis, , necroptosis, parthanatos, NETosis, disulfidptosis, and oxeiptosis are intimately linked to the onset, progression, and prognosis of AD. This review synthesizes recent advances regarding the application of PCD in biomarker identification and therapeutic innovation to enhance AD diagnosis and management. Additionally, challenges and emerging opportunities in employing PCD as novel management strategies are examined, with the overarching aim of transitioning from treatment toward prevention.

Key numbers

3-4×

Increased AD risk

Individuals with one APOEε4 allele

58–79%

AD prevalence

Estimated contribution of genetic factors to AD cases

NLRP3 involvement

Key regulator in associated with AD

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View full text (PDF) ↗View full text (HTML) ↗

Programmed cell death: a promising management for Alzheimer’s disease

Abstract

Key numbers

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the longevity & aging brief